DNA Nanobots specializes in the design and delivery of DNA nanoparticles for targeted therapeutics, addressing the inefficiencies and off-target effects associated with traditional gene therapies, vaccines, and chemotherapy. Their platform enables precise delivery of therapeutic payloads, enhancing treatment efficacy for genetic diseases and cancers.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional therapeutic delivery methods like gene therapy, vaccines, and chemotherapy often suffer from inefficiencies and off-target effects, leading to suboptimal performance and potential harm to healthy tissues. Many promising treatments for genetic diseases and cancers require enhanced tissue targeting to maximize efficacy and minimize adverse reactions.
Solution
DNA Nanobots provides a platform for designing and delivering DNA nanoparticles that enable precise and targeted delivery of therapeutic payloads. Their technology aims to improve the efficacy of various treatments, including gene therapies, vaccines, and chemotherapies, by ensuring that the therapeutic agents reach the intended cells and tissues with greater accuracy. By using custom-designed DNA nanostructures, the platform can deliver small molecule chemotherapies, proteins, peptides, or genes directly to the targeted site, reducing off-target effects and enhancing the overall therapeutic outcome. DNA Nanobots offers both partnering opportunities to integrate their delivery technology with existing therapeutics and custom development services to build tailored DNA nanostructures for specific applications.
Target Audience
The primary target audience includes biotechnology and pharmaceutical companies developing gene therapies, vaccines, chemotherapies, and other targeted therapeutics, as well as researchers and clinicians seeking advanced delivery solutions for genetic diseases and cancers.
Features
- Custom design and engineering of DNA nanobots for targeted therapeutic delivery
- DNA origami design for precise control over nanostructure shape and payload attachment
- Targeted delivery of chemotherapies, proteins, peptides, genes, and other therapeutic agents
- Non-viral gene therapy delivery using DNA nanostructures
- Capabilities for enhancing antibody-drug conjugates (ADCs)
- Expertise in immunology and engineering to optimize therapeutic solutions